Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia

Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
05 Sep 2022
bởiTristan Manalac
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.
Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
05 Sep 2022
Pandemic-fueled psych problems, fear of recurrence common among cancer patients
02 Sep 2022
Psychological problems, such as post-traumatic stress disorder (PTSD), depression, and anxiety, are common among cancer patients during the COVID-19 pandemic, as were fears of disease progression or recurrence, a recent study has found.
Pandemic-fueled psych problems, fear of recurrence common among cancer patients
02 Sep 2022
Chemoablative gel preferrable over surgery in adults with nonmuscle-invasive bladder cancer
01 Sep 2022
UGN-102, a nonsurgical, chemoablative gel used as a primary treatment for nonmuscle-invasive bladder cancer (NMIBC), is more patient-centred than standard treatments, according to a recent study.






